Quick Start — Retatrutide at a Glance
Peptide Retatrutide (LY3437943)
Class Triple Receptor Agonist — GLP-1 + GIP + Glucagon
Administration Subcutaneous injection, once weekly (same day each week)
Half-Life ~144 hours (6 days) — takes 30 days to reach steady-state
Starting Dose 0.25 mg/week, titrating up over months
Maintenance Dose 2–4 mg/week for most · trials tested up to 12 mg
Key Results 24–26% body weight loss in 48-week Phase 2 trials
Unique Advantage Glucagon agonism → direct liver fat reduction, thermogenesis, muscle preservation
Status Phase 3 trials ongoing · FDA approval projected 2026–2027
Storage Refrigerate after reconstitution · Use within 30 days
What Is Retatrutide?
Retatrutide is a once-weekly injectable peptide that simultaneously activates three metabolic receptors: GLP-1, GIP, and glucagon. This triple agonism creates a comprehensive metabolic intervention — controlling appetite, enhancing glucose metabolism, increasing energy expenditure, and directly targeting liver fat.
Early Phase 2 trials show 24–26% body weight loss over 48 weeks, making it the most potent weight management peptide tested to date. The glucagon component is what sets it apart: it increases thermogenesis (calorie burning), preserves lean muscle mass, and directly reduces liver fat — benefits not seen with GLP-1-only compounds.
Critical — Weekly Dosing Only
Retatrutide has a 144-hour (6-day) half-life. It takes 30 days of consistent weekly dosing to reach steady-state blood levels. Daily "micro-dosing" is pharmacologically impossible — the drug clears faster than it accumulates. Weekly injection is mandatory. This is not negotiable.
MechanismTriple agonist: GLP-1 + GIP + Glucagon receptor activation
Half-Life~144 hours (6 days) — requires 4–5 half-lives (30 days) to reach steady-state
RouteSubcutaneous injection (abdomen, thigh, or upper arm)
FrequencyOnce weekly — same day each week, rotate injection sites
Clinical StatusPhase 3 trials ongoing · Research compound (not yet FDA-approved)
The Triple Mechanism
Receptor 1 — GLP-1
Appetite Control & Glucose Regulation
Targets POMC neurons in the hypothalamus, suppresses Neuropeptide Y (the body's most powerful hunger signal), and slows gastric emptying for prolonged satiety. Enhances glucose-dependent insulin secretion — only when blood sugar is elevated, preventing hypoglycemia. This is not just feeling full — it reprograms the brain's definition of hunger.
Receptor 2 — GIP
Metabolic Enhancement
Amplifies insulin response to meals, improves glucose tolerance, enhances fat cell function, and reduces inflammation from adipose tissue. Works synergistically with GLP-1 to produce stronger effects than either receptor alone — the combination is greater than the sum of its parts.
Receptor 3 — Glucagon (The Differentiator)
Fat Oxidation, Thermogenesis & Liver Health
This is what separates retatrutide from everything else. Glucagon receptors are abundant in the liver. Activation triggers lipolysis (fat breakdown into energy), increases thermogenesis and energy expenditure, reduces liver fat directly through enhanced fat oxidation, and may provide anti-fibrotic benefits for fatty liver disease. The result: more fat burned, more muscle preserved, healthier liver.
Why Triple Beats Single or Dual
GLP-1 alone controls appetite but doesn't increase calorie burning. Adding GIP enhances glucose management. Adding glucagon on top creates active fat oxidation and thermogenesis — your body burns more energy even at rest. Phase 2 data confirms this translates to significantly greater weight loss and better body composition.
Research Evidence
Phase 2 Trial — Weight Loss by Dose (48 weeks)
| Weekly Dose |
Average Weight Loss |
| Placebo | 2.1% |
| 4 mg | 17.5% |
| 8 mg | 22.8% |
| 12 mg | 24.2% |
Metabolic Improvements
HbA1c Reduction-2.02% (vs -0.01% placebo)
Prediabetes Reversal72% of prediabetic participants reverted to normal glucose
Waist Circumference-10.5 cm average reduction
Blood Pressure5–10 mmHg systolic reduction
LDL Cholesterol-20% reduction
Liver Disease Trial (Nature Medicine 2024)
Liver Fat ReductionUp to 82% reduction in hepatic fat content
NASH BiomarkersSignificant improvements across markers
Anti-Fibrotic EffectsObserved through direct glucagon receptor action in liver
Reconstitution
Retatrutide is supplied as a lyophilized (freeze-dried) powder. This section covers reconstitution of a 10 mg vial with 2 mL of bacteriostatic water.
What You Need
Retatrutide Powder10 mg lyophilized vial
Bacteriostatic WaterSterile BAC water — you will use 2 mL
Insulin Syringes29–31 gauge, 0.5 mL or 1 mL (for reconstitution and weekly injections)
Alcohol SwabsFor sterilizing vial tops before every draw
Sharps ContainerFor safe syringe disposal
Important
Work on a clean surface. Sterilize vial tops with alcohol before every pierce. Inject water down the inside wall of the vial — not directly onto the powder. Gently swirl, never shake. Solution should be clear and colorless.
Step-by-Step
1
Sterilize & Draw 2 mL BAC Water
Swab both vial tops with alcohol. Draw exactly 2 mL of bacteriostatic water into your syringe.
2
Add Water to Retatrutide Vial
Pierce the vial stopper and slowly inject the BAC water down the inside wall. Do not spray directly onto the powder.
3
Dissolve Gently
Let sit 1–2 minutes. If powder remains, gently roll the vial between your palms. Never shake. Solution should be clear and colorless.
4
Label & Refrigerate
Label with: peptide name, concentration (5 mg/mL = 5,000 mcg/mL), reconstitution date, and expiry (30 days). Refrigerate at 2–8°C.
Concentration & Dosing Math
Total Retatrutide: 10 mg = 10,000 mcg
BAC water added: 2 mL
Concentration: 10,000 mcg ÷ 2 mL = 5,000 mcg/mL (5 mg/mL)
1 unit on syringe = 0.01 mL = 50 mcg Retatrutide
0.25 mg (250 mcg) = 0.05 mL = 5 units ← starting dose
0.50 mg (500 mcg) = 0.10 mL = 10 units
1.0 mg (1,000 mcg) = 0.20 mL = 20 units
2.0 mg (2,000 mcg) = 0.40 mL = 40 units ← common maintenance
4.0 mg (4,000 mcg) = 0.80 mL = 80 units
At 0.25 mg/week: 10 mg ÷ 0.25 = 40 weeks
At 1.0 mg/week: 10 mg ÷ 1.0 = 10 weeks
At 2.0 mg/week: 10 mg ÷ 2.0 = 5 weeks
At 4.0 mg/week: 10 mg ÷ 4.0 = 2.5 weeks
Quick Dosing Reference
| Weekly Dose |
Volume |
Syringe Units |
Weeks per Vial |
| 0.25 mg |
0.05 mL |
5 units |
40 weeks |
| 0.50 mg |
0.10 mL |
10 units |
20 weeks |
| 1.0 mg |
0.20 mL |
20 units |
10 weeks |
| 2.0 mg |
0.40 mL |
40 units |
5 weeks |
| 4.0 mg |
0.80 mL |
80 units |
2.5 weeks |
Practical Note
At the starting dose of 0.25 mg/week, a single 10 mg vial lasts 40 weeks. As you titrate up over months, you'll go through vials faster. At the common maintenance dose of 2 mg/week, one vial lasts about 5 weeks. Since reconstituted peptide should be used within 30 days, plan accordingly — at low starting doses you may want to reconstitute only part of a vial, or share across cycles.
Shelf Life at Low Doses
Reconstituted retatrutide should be used within 6-8 weeks.
Weekly Dosing & Titration
Injection Technique
→
Subcutaneous Injection — Once Weekly
1. Let vial reach room temperature (~15 min out of fridge)
2. Swab vial top with alcohol, draw your weekly dose
3. Choose injection site: abdomen (2+ inches from navel), thigh, or upper arm
4. Clean injection site with alcohol swab
5. Pinch a fold of skin, insert needle at 45–90° angle
6. Inject slowly, release skin, withdraw needle
7. Rotate injection sites weekly — never inject the same spot twice in a row
8. Inject on the same day each week for consistent blood levels
Titration Schedule
Start low and increase gradually. Each dose increase restarts the 30-day steady-state clock. Do not judge results before reaching steady-state at your current dose. Patience is critical.
Weeks 1–4: 0.25 mg/week (5 units) — Building toward steady-state. Mild GI effects possible. Assessing tolerance.
Weeks 5–8: 0.5 mg/week (10 units) — Continue building. GI symptoms usually improving. Appetite changes starting.
Weeks 9–12: 1.0 mg/week (20 units) — Effects becoming noticeable. Wait 30 days before next increase.
Weeks 13–16: 2.0 mg/week (40 units) — Common maintenance dose for many users. Assess if further increase needed.
Weeks 17+: 2–4 mg/week (40–80 units) — Maintenance. Some may benefit from 4–8 mg. Clinical trials tested up to 12 mg.
| Phase |
Weeks |
Dose |
Units |
Purpose |
| Start |
1–4 |
0.25 mg |
5 |
Tolerance assessment, initial steady-state |
| Low |
5–8 |
0.5 mg |
10 |
Gradual escalation, GI adaptation |
| Medium |
9–12 |
1.0 mg |
20 |
Effects becoming apparent |
| Maintenance |
13–16 |
2.0 mg |
40 |
Common maintenance for most users |
| Advanced |
17+ |
2–4 mg |
40–80 |
Optimized maintenance based on response |
The Bathtub Analogy — Why Weekly Dosing Matters
Think of your body as a bathtub. The weekly injection is the faucet, and your metabolism is the drain. With proper weekly dosing, water accumulates faster than the drain removes it — the tub fills to therapeutic level in ~30 days. With daily micro-dosing, you add tiny drops that the drain removes faster than they accumulate — the tub never fills. You never reach the therapeutic concentration. Weekly dosing is mandatory.
Missed Dose
Take it as soon as you remember if within 3 days. If more than 3 days late, skip and resume your normal schedule next week. Never double-dose.
Week-by-Week Expectations
Weeks 1–4: Foundation (2–4% weight loss)
GI side effects peak then improve (nausea, reduced appetite). Energy may dip initially. Appetite begins decreasing. Building toward first steady-state. Don't judge results yet.
Weeks 5–8: Momentum (6–10% weight loss)
Steady appetite suppression established. Side effects minimal for most. Energy normalizes or improves. Body starting to use fat for fuel via glucagon activation.
Weeks 9–16: Transformation (12–18% weight loss)
Noticeable body composition changes. Clothes fitting differently. Metabolic markers (blood glucose, cholesterol, liver enzymes) improving. This is where the triple mechanism shows its full effect.
Weeks 17–48: Optimization (20–26% weight loss)
Approaching maximum effect at full dose. Plateau periods are normal — don't panic. Focus shifts to maintenance and long-term habit formation. The habits you build during treatment determine success after treatment.
Weight Regain Warning
Research shows 60–70% of users regain significant weight within 12 months if stopping abruptly without lifestyle changes. Gradual taper plus high protein intake and resistance training dramatically improve long-term outcomes. Build sustainable habits during treatment — retatrutide is a tool, not a permanent solution.
Stacking Strategies
Retatrutide 2–4 mg weekly (titrated up from 0.25 mg)
High Protein Diet 1.2–1.6 g/kg bodyweight daily (non-negotiable)
Resistance Training 3–4x weekly (progressive overload)
This is the foundation. Everything else stacks on top of this. Without protein and training, you lose muscle alongside fat.
Retatrutide 2–4 mg weekly
CJC-1295 / Ipamorelin 200/200 mcg before bed (stimulates GH for recovery)
Creatine 5g daily (muscle energy, water retention in muscle tissue)
Leucine 3g with each protein-rich meal (mTOR activation for muscle protein synthesis)
Best for: anyone wanting to preserve or build muscle during aggressive fat loss. Clinical experience shows superior body composition outcomes.
Retatrutide 4–8 mg weekly (higher dose for liver focus)
NAD+ 500 mg IV/SubQ, 2x weekly (mitochondrial health)
TUDCA 500 mg daily (bile acid support, liver cell protection)
Best for: NAFLD/fatty liver disease, elevated liver enzymes, metabolic syndrome. Glucagon agonism directly targets hepatic fat — this stack amplifies that pathway.
Retatrutide 2–4 mg weekly
BPC-157 250 mcg daily (joint, tendon, and gut healing)
TB-500 2 mg twice weekly (systemic recovery and inflammation)
Progressive Overload Training 4x weekly
Best for: those training hard during a caloric deficit. Healing peptides protect joints and tendons, allowing sustained training intensity without injury risk.
Retatrutide 2 mg weekly (lower dose, metabolic health focus)
GHK-Cu 2 mg twice weekly (collagen, skin, healing)
Epitalon 10 mg for 10-day cycles, quarterly (telomere support)
MOTS-C 5 mg twice weekly (mitochondrial function)
Best for: longevity-focused users not seeking aggressive weight loss. Improves insulin sensitivity, cellular health, and metabolic markers at a sustainable pace.
Safety & Side Effects
Common Side Effects (30–60% of users)
Most side effects are GI-related and improve significantly after weeks 1–4 as the body adapts. Starting at a low dose and titrating slowly minimizes these dramatically.
NauseaMost common, especially weeks 1–4. Improves with time. Eat smaller meals, avoid fatty foods initially, stay hydrated.
Diarrhea / ConstipationGI motility changes. Usually normalizes. Increase fiber and water intake.
Abdominal DiscomfortGastric emptying is slowed. Smaller, more frequent meals help significantly.
FatigueFirst 2–4 weeks as body adapts to metabolic shift. Normalizes.
Injection Site ReactionsMild redness or pain. Rotate sites weekly. Let solution reach room temperature before injecting.
Serious But Rare
PancreatitisExtremely rare but serious. Stop immediately if severe abdominal pain radiating to back.
Gallbladder IssuesRapid weight loss increases gallstone risk. Monitor for right upper quadrant pain.
HypoglycemiaRare alone. Higher risk if combined with insulin or sulfonylureas.
Do Not Use If
Personal or family history of medullary thyroid carcinoma (MTC) · Multiple Endocrine Neoplasia type 2 (MEN2) · Pregnant or planning pregnancy · History of pancreatitis · Severe gastroparesis · Type 1 diabetes (not studied). Black box warning exists on related GLP-1 compounds for thyroid C-cell tumors.
Storage & Monitoring
Storage
Lyophilized (Powder)Freezer (-20°C) for long-term or refrigerator (2–8°C). Stable for months sealed.
ReconstitutedRefrigerate at 2–8°C. Use within 30 days. Do not freeze reconstituted solution.
Protect FromLight, heat, repeated temperature swings.
Signs of DegradationCloudiness, discoloration, particles — discard immediately.
Recommended Blood Work
| When |
Tests |
| Baseline (before starting) |
Comprehensive metabolic panel, lipid panel, HbA1c, thyroid function (TSH), liver enzymes (ALT/AST) |
| Monthly (first 3 months) |
Weight, blood pressure, heart rate, blood glucose (if diabetic/prediabetic), side effect assessment |
| Quarterly (ongoing) |
Full metabolic panel, HbA1c, lipid panel, liver function, thyroid function |
Frequently Asked Questions
Can I micro-dose daily?No. The 144-hour half-life requires weekly dosing to reach steady-state. Daily micro-dosing will not work — the drug clears faster than it accumulates.
How long until results?30 days to reach first steady-state. Noticeable weight loss by 6–8 weeks. Maximum effects at 16–24 weeks.
Will I regain weight?60–70% regain if stopping abruptly without lifestyle change. Gradual taper + high protein + resistance training dramatically improves outcomes.
Can I build muscle?Yes — if protein is high (1.2–1.6 g/kg) and resistance training is consistent. Retatrutide preserves more lean mass than GLP-1-only compounds.
Do I need to cycle?No cycling required. Clinical trials ran 48+ weeks continuous. Gradual taper recommended when stopping.
What if I miss a dose?Take within 3 days of missed day. If more than 3 days late, skip and resume next week. Never double-dose.
Is it safe long-term?Phase 3 data pending. GLP-1 drugs have 10+ year safety data. Glucagon agonism is newer. Monitor with blood work.
Success Factors
High Success Probability
Follow weekly dosing protocol · High protein intake (1.2–1.6 g/kg) · Resistance train 3–4x/week · Gradual taper when stopping · Build sustainable habits during treatment
Poor Results Likely
Daily micro-dosing · Skipping doses randomly · Zero protein/training focus · Expecting permanent results without habit change · Abrupt discontinuation
Disclaimer: This information is for educational and research purposes only. Retatrutide is not FDA-approved and is a research compound undergoing Phase 3 clinical trials. This guide does not constitute medical advice. Individual responses vary significantly. Always consult with a qualified healthcare professional before starting any peptide protocol, especially if you have thyroid conditions, history of pancreatitis, diabetes, or take prescription medications. Not for use by pregnant individuals or those with MTC/MEN2 family history. Competitive athletes should verify current WADA status.
|
